{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T20:44:15Z","timestamp":1792615455490,"version":"4.5.0"},"reference-count":79,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82503756"],"award-info":[{"award-number":["82503756"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Cancer"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.trecan.2026.09.010","type":"journal-article","created":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T19:29:17Z","timestamp":1792524557000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Bispecific antibodies in NSCLC: immune reengineering to neutralize adaptive tumor resistance"],"prefix":"10.1016","author":[{"given":"Zetong","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haowei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Diao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruixuan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anwen","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caicun","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9368-7192","authenticated-orcid":false,"given":"Zhuoran","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.trecan.2026.09.010_bb0005","doi-asserted-by":"crossref","first-page":"e5","DOI":"10.1634\/theoncologist.2014-0241","article-title":"FDA approval summary: crizotinib for the treatment of metastatic non-small cell lung cancer with anaplastic lymphoma kinase rearrangements","volume":"19","author":"Kazandjian","year":"2014","journal-title":"Oncologist"},{"key":"10.1016\/j.trecan.2026.09.010_bb0010","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1634\/theoncologist.2015-0507","article-title":"FDA approval summary: nivolumab for the treatment of metastatic non-small cell lung cancer with progression on or after platinum-based chemotherapy","volume":"21","author":"Kazandjian","year":"2016","journal-title":"Oncologist"},{"key":"10.1016\/j.trecan.2026.09.010_bb0015","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.trecan.2026.09.010_bb0020","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/nchembio.118","article-title":"Network pharmacology: the next paradigm in drug discovery","volume":"4","author":"Hopkins","year":"2008","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.trecan.2026.09.010_bb0025","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1158\/1078-0432.CCR-22-1366","article-title":"Molecular mechanisms and future implications of VEGF\/VEGFR in cancer therapy","volume":"29","author":"Patel","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.trecan.2026.09.010_bb0030","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aay0555","article-title":"VEGF-A drives TOX-dependent T cell exhaustion in anti-PD-1-resistant microsatellite stable colorectal cancers","volume":"4","author":"Kim","year":"2019","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.trecan.2026.09.010_bb0035","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1158\/2326-6066.CIR-19-0360","article-title":"Anti-VEGF treatment enhances CD8+ T-cell antitumor activity by amplifying hypoxia","volume":"8","author":"de Almeida","year":"2020","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.trecan.2026.09.010_bb0040","doi-asserted-by":"crossref","first-page":"3845","DOI":"10.7150\/ijbs.70958","article-title":"VEGF\/VEGFR-targeted therapy and immunotherapy in non-small cell lung cancer: targeting the tumor microenvironment","volume":"18","author":"Zhao","year":"2022","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.trecan.2026.09.010_bb0045","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1001\/jama.2026.7745","article-title":"Bispecific antibody ivonescimab added to chemotherapy in EGFR-variant non-small cell lung cancer: the HARMONi-A randomized clinical trial","volume":"336","author":"Investigators","year":"2026","journal-title":"JAMA"},{"key":"10.1016\/j.trecan.2026.09.010_bb0050","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(24)02722-3","article-title":"Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China","volume":"405","author":"Xiong","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.trecan.2026.09.010_bb0055","doi-asserted-by":"crossref","first-page":"2620","DOI":"10.1016\/S0140-6736(26)00966-9","article-title":"Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy in advanced squamous non-small-cell lung cancer (HARMONi-6): interim overall survival analysis of a randomised, double-blind, phase 3 trial in China","volume":"407","author":"Lu","year":"2026","journal-title":"Lancet"},{"key":"10.1016\/j.trecan.2026.09.010_bb0060","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.16_suppl.TPS8664","article-title":"A randomized phase 3 study of ivonescimab plus chemotherapy versus pembrolizumab plus chemotherapy for the first-line treatment of metastatic non\u2013small cell lung cancer: HARMONi-3","volume":"43","author":"Zhang","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.trecan.2026.09.010_bb0065","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/s13046-020-01611-0","article-title":"Regulation of heterogeneous cancer-associated fibroblasts: the molecular pathology of activated signaling pathways","volume":"39","author":"Yoshida","year":"2020","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.trecan.2026.09.010_bb0070","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s12943-022-01569-x","article-title":"Targeting TGF-\u03b2 signal transduction for fibrosis and cancer therapy","volume":"21","author":"Peng","year":"2022","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.trecan.2026.09.010_bb0075","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.1158\/2159-8290.CD-21-1714","article-title":"Spatial positioning and matrix programs of cancer-associated fibroblasts promote T-cell exclusion in human lung tumors","volume":"12","author":"Grout","year":"2022","journal-title":"Cancer Discov."},{"key":"10.1016\/j.trecan.2026.09.010_bb0080","doi-asserted-by":"crossref","first-page":"4520","DOI":"10.1038\/s41467-020-18298-8","article-title":"Collagen promotes anti-PD-1\/PD-L1 resistance in cancer through LAIR1-dependent CD8+ T cell exhaustion","volume":"11","author":"Peng","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.trecan.2026.09.010_bb0085","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1016\/j.jtho.2023.08.018","article-title":"Bintrafusp alfa versus pembrolizumab in patients with treatment-naive, programmed death-ligand 1-high advanced NSCLC: a randomized, open-label, phase 3 trial","volume":"18","author":"Cho","year":"2023","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.trecan.2026.09.010_bb0090","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/s41392-026-02779-1","article-title":"Neoadjuvant retlirafusp alfa (anti-PD-L1\/TGF-\u03b2 bifunctional fusion protein) with or without chemotherapy in unresectable stage III non-small cell lung cancer: updated results from the phase 2 TRAILBLAZER trial","volume":"11","author":"Pan","year":"2026","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.trecan.2026.09.010_bb0095","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.lungcan.2021.02.026","article-title":"The evolving landscape of biomarker testing for non-small cell lung cancer in Europe","volume":"154","author":"Kerr","year":"2021","journal-title":"Lung Cancer"},{"key":"10.1016\/j.trecan.2026.09.010_bb0100","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s40364-024-00566-0","article-title":"Oncogenic alterations in advanced NSCLC: a molecular super-highway","volume":"12","author":"Friedlaender","year":"2024","journal-title":"Biomark. Res."},{"key":"10.1016\/j.trecan.2026.09.010_bb0105","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1038\/s41467-023-35961-y","article-title":"Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer","volume":"14","author":"Chmielecki","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.trecan.2026.09.010_bb0110","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1186\/s12943-025-02493-6","article-title":"IFITM3-MET interaction drives osimertinib resistance through AKT pathway activation in EGFR-mutant non-small cell lung cancer","volume":"24","author":"Ibusuki","year":"2025","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.trecan.2026.09.010_bb0115","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1158\/1535-7163.MCT-20-0071","article-title":"Amivantamab (JNJ-61186372), an Fc enhanced EGFR\/cMet bispecific antibody, induces receptor downmodulation and antitumor activity by monocyte\/macrophage trogocytosis","volume":"19","author":"Vijayaraghavan","year":"2020","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.trecan.2026.09.010_bb0120","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1056\/NEJMoa2306441","article-title":"Amivantamab plus chemotherapy in NSCLC with EGFR exon 20 insertions","volume":"389","author":"Zhou","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.trecan.2026.09.010_bb0125","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1056\/NEJMoa2403614","article-title":"Amivantamab plus lazertinib in previously untreated EGFR-mutated advanced NSCLC","volume":"391","author":"Cho","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.trecan.2026.09.010_bb0130","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1056\/NEJMoa2503001","article-title":"Overall survival with amivantamab-lazertinib in EGFR-mutated advanced NSCLC","volume":"393","author":"Yang","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.trecan.2026.09.010_bb0135","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.annonc.2024.05.541","article-title":"Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a secondary analysis from MARIPOSA","volume":"35","author":"Felip","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.trecan.2026.09.010_bb0140","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.annonc.2023.10.117","article-title":"Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study","volume":"35","author":"Passaro","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.trecan.2026.09.010_bb0145","doi-asserted-by":"crossref","first-page":"9552","DOI":"10.1038\/s41598-024-55829-5","article-title":"A real-world pharmacovigilance study of amivantamab-related cardiovascular adverse events based on the FDA adverse event reporting system (FAERS) database","volume":"14","author":"Sun","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.trecan.2026.09.010_bb0150","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.957874","article-title":"Dual Fc optimization to increase the cytotoxic activity of a CD19-targeting antibody","volume":"13","author":"Gehlert","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.trecan.2026.09.010_bb0155","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/S0140-6736(23)00521-4","article-title":"T-cell-engaging bispecific antibodies in cancer","volume":"402","author":"van de Donk","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.trecan.2026.09.010_bb0160","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1158\/1078-0432.CCR-25-2287","article-title":"FDA approval summary: tarlatamab for the treatment of extensive-stage small cell lung cancer","volume":"32","author":"Liu","year":"2026","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.trecan.2026.09.010_bb0165","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1056\/NEJMoa2502099","article-title":"Tarlatamab in small-cell lung cancer after platinum-based chemotherapy","volume":"393","author":"Mountzios","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.trecan.2026.09.010_bb0170","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2025.2531223","article-title":"Innovative strategies for T cell engagers for cancer immunotherapy","volume":"17","author":"Bergamaschi","year":"2025","journal-title":"MAbs"},{"key":"10.1016\/j.trecan.2026.09.010_bb0175","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s12943-023-01740-y","article-title":"Lung cancer immunotherapy: progress, pitfalls, and promises","volume":"22","author":"Lahiri","year":"2023","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.trecan.2026.09.010_bb0180","volume":"16","author":"Lin","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.trecan.2026.09.010_bb0185","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1186\/s13045-023-01507-4","article-title":"Nanobody-based trispecific T cell engager (nb-TriTE) enhances therapeutic efficacy by overcoming tumor-mediated immunosuppression","volume":"16","author":"Ding","year":"2023","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.trecan.2026.09.010_bb0190","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.24.01001","volume":"42","author":"Leighl","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.trecan.2026.09.010_bb0195","doi-asserted-by":"crossref","first-page":"8604","DOI":"10.1200\/JCO.2024.42.16_suppl.8604","article-title":"Efficacy and safety of MCLA-129, an EGFR\/c-MET bispecific antibody, in advanced non-small cell lung cancer (NSCLC)","volume":"42","author":"Wang","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.trecan.2026.09.010_bb0200","doi-asserted-by":"crossref","first-page":"S756","DOI":"10.1016\/j.annonc.2023.09.2349","article-title":"1315MO durable efficacy of zenocutuzumab, a HER2 \u00d7 HER3 bispecific antibody, in advanced NRG1 fusion-positive (NRG1+) non-small cell lung cancer (NSCLC)","volume":"34","author":"Schram","year":"2023","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.trecan.2026.09.010_bb0205","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1007\/s40265-025-02155-3","article-title":"Zenocutuzumab: first approval","volume":"85","author":"Blair","year":"2025","journal-title":"Drugs"},{"key":"10.1016\/j.trecan.2026.09.010_bb0210","doi-asserted-by":"crossref","first-page":"8533","DOI":"10.1200\/JCO.2024.42.16_suppl.8533","article-title":"A phase Ib\/IIa trial to evaluate the safety and efficacy of PM8002, a bispecific antibody targeting PD-L1 and VEGF-A, as a monotherapy in patients with advanced NSCLC","volume":"42","author":"Wu","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.trecan.2026.09.010_bb0215","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.16_suppl.TPS8670","article-title":"A global phase 2\/3, randomized, open-label trial of BNT327\/PM8002 in combination with chemotherapy (chemo) in first-line (1L) non-small cell lung cancer (NSCLC)","volume":"43","author":"Peters","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.trecan.2026.09.010_bb0220","doi-asserted-by":"crossref","first-page":"8543","DOI":"10.1200\/JCO.2025.43.16_suppl.8543","article-title":"A phase II trial to evaluate the safety and efficacy of SSGJ-707, a bispecific antibody targeting PD-1 and VEGF, as a monotherapy in patients with advanced NSCLC","volume":"43","author":"Wu","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.trecan.2026.09.010_bb0225","doi-asserted-by":"crossref","first-page":"8514","DOI":"10.1200\/JCO.2026.44.16_suppl.8514","article-title":"Updated results from a phase 2 trial of SSGJ-707 (PF-08634404), a PD-1\/VEGF bispecific antibody, as monotherapy in patients with advanced non-small cell lung cancer (NSCLC)","volume":"44","author":"Wu","year":"2026","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.trecan.2026.09.010_bb0230","article-title":"KN046, a bispecific antibody against PD-L1 and CTLA-4, plus chemotherapy as first-line treatment for metastatic NSCLC: a multicenter phase 2 trial","volume":"5","author":"Zhao","year":"2024","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.trecan.2026.09.010_bb0235","doi-asserted-by":"crossref","first-page":"4449","DOI":"10.1158\/1078-0432.CCR-22-3667","article-title":"Dissecting the mechanisms underlying the cytokine release syndrome (CRS) mediated by T-cell bispecific antibodies","volume":"29","author":"Leclercq-Cohen","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.trecan.2026.09.010_bb0240","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1007\/s00262-025-04080-6","article-title":"Predictive factors and nomogram for the risk of cytokine release syndrome with anti-CD3\u00d7CD20 bispecific antibodies for Chinese patients","volume":"74","author":"Sun","year":"2025","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.trecan.2026.09.010_bb0245","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1182\/blood-2024-206054","article-title":"Exposure-response (ER) and pharmacokinetic\/pharmacodynamic (PK\/PD) analyses for optimal step-up dose (SUD) selection to improve cytokine release syndrome (CRS) safety profile of Abbv-383 in patients with relapsed or refractory multiple myeloma (RRMM)","volume":"144","author":"Wang","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.trecan.2026.09.010_bb0250","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2019.102625","article-title":"DuoBody-CD3xCD20 induces potent T-cell-mediated killing of malignant B cells in preclinical models and provides opportunities for subcutaneous dosing","volume":"52","author":"Engelberts","year":"2020","journal-title":"EBioMedicine"},{"key":"10.1016\/j.trecan.2026.09.010_bb0255","doi-asserted-by":"crossref","first-page":"259","DOI":"10.3390\/cancers17020259","article-title":"Prevention and treatment of venous thromboembolism associated with amivantamab-based therapies in patients with lung cancer-provisional clinical opinion based on existing clinical practice guidelines","volume":"17","author":"Moik","year":"2025","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.trecan.2026.09.010_bb0260","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005924","article-title":"Liquid biopsy approaches to capture tumor evolution and clinical outcomes during cancer immunotherapy","volume":"11","author":"Sivapalan","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.trecan.2026.09.010_bb0265","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-006234","article-title":"Spatial multi-omics revealed the impact of tumor ecosystem heterogeneity on immunotherapy efficacy in patients with advanced non-small cell lung cancer treated with bispecific antibody","volume":"11","author":"Song","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.trecan.2026.09.010_bb0270","doi-asserted-by":"crossref","first-page":"9701","DOI":"10.1038\/s41467-025-65783-z","article-title":"AI-powered spatial cell phenomics enhances risk stratification in non-small cell lung cancer","volume":"16","author":"Schallenberg","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.trecan.2026.09.010_bb0275","doi-asserted-by":"crossref","first-page":"3787","DOI":"10.1021\/acs.chemrev.9b00738","article-title":"ImmunoPET: concept, design, and applications","volume":"120","author":"Wei","year":"2020","journal-title":"Chem. Rev."},{"key":"10.1016\/j.trecan.2026.09.010_bb0280","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s12885-021-09111-w","article-title":"Digital gene expression analysis of NSCLC-patients reveals strong immune pressure, resulting in an immune escape under immunotherapy","volume":"22","author":"Wessolly","year":"2022","journal-title":"BMC Cancer"},{"key":"10.1016\/j.trecan.2026.09.010_bb0285","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s13045-019-0759-9","article-title":"MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer","volume":"12","author":"Wang","year":"2019","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.trecan.2026.09.010_bb0290","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1016\/j.ccell.2023.05.015","article-title":"MCT4-dependent lactate secretion suppresses antitumor immunity in LKB1-deficient lung adenocarcinoma","volume":"41","author":"Qian","year":"2023","journal-title":"Cancer Cell"},{"key":"10.1016\/j.trecan.2026.09.010_bb0295","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1007\/s12272-025-01545-1","article-title":"Targeting vascular endothelial growth receptor-2 (VEGFR-2): structural biology, functional insights, and therapeutic resistance","volume":"48","author":"Shah","year":"2025","journal-title":"Arch. Pharm. Res."},{"key":"10.1016\/j.trecan.2026.09.010_bb0300","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s12079-016-0352-8","article-title":"VEGF-A\/VEGFR2 signaling network in endothelial cells relevant to angiogenesis","volume":"10","author":"Abhinand","year":"2016","journal-title":"J. Cell. Commun. Signal"},{"key":"10.1016\/j.trecan.2026.09.010_bb0305","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20190103","article-title":"Transforming growth factor-\u03b2 in tissue fibrosis","volume":"217","author":"Frangogiannis","year":"2020","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.trecan.2026.09.010_bb0310","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.3390\/biom10121666","article-title":"Transforming growth factor-\u03b2 signaling in fibrotic diseases and cancer-associated fibroblasts","volume":"10","author":"Shi","year":"2020","journal-title":"Biomolecules"},{"key":"10.1016\/j.trecan.2026.09.010_bb0315","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1158\/1535-7163.MCT-21-0201","article-title":"Characterization of KRAS mutation subtypes in non-small cell lung cancer","volume":"20","author":"Judd","year":"2021","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.trecan.2026.09.010_bb0320","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1056\/NEJMoa2105281","article-title":"Acquired resistance to KRASG12C inhibition in cancer","volume":"384","author":"Awad","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.trecan.2026.09.010_bb0325","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/s41586-021-04065-2","article-title":"Diverse alterations associated with resistance to KRAS(G12C) inhibition","volume":"599","author":"Zhao","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.trecan.2026.09.010_bb0330","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1158\/2159-8290.CD-19-1167","article-title":"The KRASG12C inhibitor MRTX849 provides insight toward therapeutic susceptibility of KRAS-mutant cancers in mouse models and patients","volume":"10","author":"Hallin","year":"2020","journal-title":"Cancer Discov."},{"key":"10.1016\/j.trecan.2026.09.010_bb0335","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adl6464","article-title":"Spatial multiplex analysis of lung cancer reveals that regulatory T cells attenuate KRAS-G12C inhibitor-induced immune responses","volume":"10","author":"Cole","year":"2024","journal-title":"Sci. Adv."},{"key":"10.1016\/j.trecan.2026.09.010_bb0340","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1016\/j.jtho.2023.05.013","article-title":"Brief report: severe sotorasib-related hepatotoxicity and non-liver adverse events associated with sequential anti-programmed cell death (Ligand)1 and sotorasib therapy in KRASG12C-mutant lung cancer","volume":"18","author":"Chour","year":"2023","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.trecan.2026.09.010_bb0345","article-title":"Bispecific antibodies combined with chemotherapy in solid tumor treatment, the path forward?","volume":"16","author":"Yan","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.trecan.2026.09.010_bb0350","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1038\/s41586-019-1032-7","article-title":"Neoantigen-directed immune escape in lung cancer evolution","volume":"567","author":"Rosenthal","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.trecan.2026.09.010_bb0355","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005018","article-title":"Bispecific antibodies targeting CD40 and tumor-associated antigens promote cross-priming of T cells resulting in an antitumor response superior to monospecific antibodies","volume":"10","author":"H\u00e4gerbrand","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.trecan.2026.09.010_bb0360","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1158\/1078-0432.CCR-20-3305","article-title":"Entinostat plus pembrolizumab in patients with metastatic NSCLC previously treated with anti-PD-(L)1 therapy","volume":"27","author":"Hellmann","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.trecan.2026.09.010_bb0365","doi-asserted-by":"crossref","first-page":"9125","DOI":"10.1200\/JCO.2023.41.16_suppl.9125","article-title":"Phase II randomized trial of first-line pembrolizumab and vorinostat in patients with metastatic NSCLC (mNSCLC)","volume":"41","author":"Saltos","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.trecan.2026.09.010_bb0370","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1038\/s41588-024-01880-x","article-title":"Epigenetic therapy potentiates transposable element transcription to create tumor-enriched antigens in glioblastoma cells","volume":"56","author":"Jang","year":"2024","journal-title":"Nat. Genet."},{"key":"10.1016\/j.trecan.2026.09.010_bb0375","doi-asserted-by":"crossref","first-page":"25106","DOI":"10.1074\/jbc.M116.753491","article-title":"Balancing selectivity and efficacy of bispecific epidermal growth factor receptor (EGFR) \u00d7 c-MET antibodies and antibody-drug conjugates","volume":"291","author":"Sellmann","year":"2016","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.trecan.2026.09.010_bb0380","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/s41571-023-00850-2","article-title":"Exploring the next generation of antibody-drug conjugates","volume":"21","author":"Tsuchikama","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.trecan.2026.09.010_bb0385","article-title":"Targeting dual immune checkpoints PD-L1 and HLA-G by trispecific T cell engager for treating heterogeneous lung cancer","volume":"11","author":"Lin","year":"2024","journal-title":"Adv. Sci. (Weinh.)"},{"key":"10.1016\/j.trecan.2026.09.010_bb0390","doi-asserted-by":"crossref","first-page":"5632","DOI":"10.3390\/ijms22115632","article-title":"Principles and current clinical landscape of multispecific antibodies against cancer","volume":"22","author":"Elshiaty","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.trecan.2026.09.010_bb0395","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/s41392-021-00868-x","article-title":"Emerging new therapeutic antibody derivatives for cancer treatment","volume":"7","author":"Jin","year":"2022","journal-title":"Signal Transduct. Target. Ther."}],"container-title":["Trends in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405803326002219?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405803326002219?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T19:59:54Z","timestamp":1792612794000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405803326002219"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":79,"alternative-id":["S2405803326002219"],"URL":"https:\/\/doi.org\/10.1016\/j.trecan.2026.09.010","relation":{},"ISSN":["2405-8033"],"issn-type":[{"value":"2405-8033","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bispecific antibodies in NSCLC: immune reengineering to neutralize adaptive tumor resistance","name":"articletitle","label":"Article Title"},{"value":"Trends in Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.trecan.2026.09.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}